MTACs
MTACs are novel bifunctional molecules containing a proprietary Avilar ligand to the mannose 6-phosphate receptor (M6PR) conjugated to a second ligand that binds to a protein of interest for degradation. MTACs drive the uptake and degradation of pathogenic proteins in the endolysosome of M6PR-expressing cells, which include hepatocytes but also encompass multiple additional cell types.
Avilar’s high affinity ligands to M6PR form the chemistry backbone for MTACs and enable the synthesis of degraders with more streamlined monovalent designs, lower molecular weight, and improved physicochemical properties versus previous approaches. Complementary to ATACs, MTACs expand the scope of targets addressable by Avilar by enabling the degradation of non-hepatocyte membrane proteins.